Syntis Bio
Syntis Bio is a clinical-stage biopharmaceutical company in Boston, Massachusetts developing oral therapies that use the small intestine as a delivery site. Its SYNT platform (Synthetic Tissue-lining) applies a mussel-inspired polydopamine polymer coating transiently to specific tissues in the GI tract, sustaining therapeutic activity for up to 24 hours before being naturally cleared. The platform is being applied to nutrient exclusion for obesity, gut-restricted enzyme replacement for rare metabolic disorders such as homocystinuria and maple syrup urine disease, and oral bioavailability enhancement for peptides and biologics. Lead candidate SYNT-101 is a once-daily oral pill intended to mimic aspects of gastric bypass by transiently blocking nutrient absorption in the duodenum. The company was co-founded in 2022 by MIT's Robert Langer and Giovanni Traverso with CEO Rahul Dhanda. Syntis Bio is a therapeutics developer and publishes no public API, developer program, SDK, or machine-readable specification.
Syntis Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Drug Delivery.
Syntis Bio’s developer surface includes engineering blog and 10 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Commercial 2
Pricing, plans, and the legal terms of use
Company 7
The organization behind the API
Scroll for all 7
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.